Management of Hot Flashes in Postpartum Period

First-Line Pharmacological Options

The American College of Obstetricians and Gynecologists recommends venlafaxine (75 mg/day) as a first-line treatment for hot flashes in postpartum women, reducing hot flash severity by up to 61% 1
The National Comprehensive Cancer Network recommends starting with a lower dose of venlafaxine (37.5 mg) and increasing to 75 mg after 1 week if greater symptom control is needed 2, 3
Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), such as paroxetine (7.5-12.5 mg daily), can reduce hot flash frequency and severity by 40-62% 5

Gabapentin (900 mg/day) has been shown to decrease hot flash severity by 46% at 8 weeks compared to 15% with placebo, with side effects including somnolence and dizziness 4, 3, 6
Clonidine (0.1 mg/day oral or transdermal) can reduce hot flash frequency and severity, with efficacy up to 46% reduction, but may have side effects including dry mouth, insomnia or drowsiness 6

Head-to-head studies show venlafaxine and gabapentin have similar efficacy in reducing hot flash severity, but 68% of participants preferred venlafaxine over gabapentin (32%) 4, 1
The National Comprehensive Cancer Network reports that clonidine has an efficacy of 0.95 fewer hot flashes per day vs placebo, while SSRI/SNRI has an efficacy of 1.13 fewer hot flashes per day vs placebo, and gabapentin has an efficacy of 2.05 fewer hot flashes per day vs placebo 6, 1

Acupuncture has been found to be equivalent to or better than venlafaxine or gabapentin in several comparative studies, and may be considered as an adjunct to pharmacological treatment or as an alternative for those who prefer non-drug approaches 4, 1
Yoga may improve quality of life associated with menopausal symptoms, including vasomotor symptoms, and weight loss if overweight or obese and smoking cessation can improve frequency and severity of hot flashes 4, 1

The treatment algorithm recommends starting with venlafaxine 37.5 mg/day, increasing to 75 mg/day after one week if needed, with alternative first-line options including gabapentin 900 mg/day if sexual dysfunction is a concern 2, 1, 6

When treating nursing mothers, consider potential effects on breastfeeding and infant exposure through breast milk, and gradual tapering of SNRIs and SSRIs is recommended when discontinuing to minimize withdrawal symptoms 2, 4

Assess response to treatment after 4 weeks, and monitor for side effects, particularly in the first week of treatment, with consideration for evaluation of other causes of vasomotor symptoms if symptoms persist despite adequate treatment 2, 5, 4, 1